Bristol-Myers Squibb, Pfizer say analysis indicates lower risk of stroke, major bleeding using Eliquis vs. warfarin
Bristol-Myers Squibb and Pfizer said Eliquis (apixaban) showed a significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin in an analysis of Medicare data involving patients with non-valvular atrial fibrillation.
The analysis, titled "Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin among Non-Valvular Atrial Fibrillation Patients in the U.S. Medicare Population," looked at medical and pharmacy requests of people fighting non-valvular atrial fibrillation who were listed in the Medicare fee-for-service listings, a Bristol-Myers Squibb release said. The 41,606 non-valvular atrial fibrillation patients, whose average age was 78, got prescriptions for blood thinners taken by mouth. Of those patients, took Eliquis and half took warfarin.
The analysis of the data showed that those who took Eliquis were far less likely to experience a stroke or systemic embolism and experienced significant bleeding at a lower percentage than those who took warfarin, the release said.
Organizations in this story
Bristol-Myers Squibb 345 Park Ave NY, NY - 10154